Navigation Links
VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
Date:11/26/2007

BASKING RIDGE, N.J., Nov. 26 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals (OTC Bulletin Board: VQPH) today announced the initiation of a Phase IIa study of Lenocta(TM) (sodium stibogluconate), a novel protein tyrosine phosphatase inhibitor, in combination with interferon alpha, an immune stimulant approved for the treatment of hepatitis C, hepatitis B and a number of cancers. The open-label Phase IIa study is designed to enroll at least 12 more patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGO )

The Phase IIa trial will evaluate the clinical efficacy and biological effectiveness of Lenocta at the highest tolerable dose in combination with interferon alpha in patients with advanced-stage solid tumors.

"We have reached a significant milestone in the development of Lenocta as a potential cancer therapy with the initiation of this trial," said Michael D. Becker, President and Chief Executive Officer of VioQuest Pharmaceuticals. "We will continue to advance our portfolio of novel compounds for various cancer indications into clinical development, the goal of this drug development organization."

Razelle Kurzrock M.D., Professor of Medicine Chair, Department of Investigational Cancer Therapeutics at The University of Texas M.D. Anderson Cancer Center is the lead principal investigator for the study, while Aung Naing M.D. of the same institution and Claire Verschraegen M.D. of The University of New Mexico Cancer Center are participating co-principal investigators.

Data from the recently concluded Phase I trial for Lenocta demonstrated pharmacodynamic activity in some solid tumors as demonstrated by increases in the activities of natural killer cells, CD8 and type II dendritic cells.

About Lenocta

Lenocta, a pentavalent antimonial originally used for the treatment of the parasitic disease leishmaniasis, is an
'/>"/>

SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008).... 1 Vical Incorporated (...$1.0 million milestone payment from Merck & Co...hase I clinical trial of an investigational plasmi... is based on Vical,s DNA gene delivery technology ... (hTERT). hTERT is the subject of separate license...
(Date:11/28/2008)...Nov. 28 Eli Lilly and Co...al New Drug Application (sNDA) from,the U.S. Food...loxetine HCl),for the management of chronic pain....irst half of 2009, adding data from a recently com...ain of the knee. , The decision does not af...
(Date:11/26/2008)... to 406 Subjects , , FRANKLIN, Mass., Nov. ... Bulletin Board: PLCSF) announced today that it ha...ug Administration (FDA) for its U.S. pivotal trial...Guard System(TM) and associated therapy in the pr... , The FDA also approved PLC,s request to ex...
(Date:11/25/2008)...CISCO, Calif., Nov. 25 Proteolix, ...f novel therapeutics that target,protein degradat...day,announced that data from two ongoing Phase 2 ...a will be presented at the upcoming 50th Annual Me.... Carfilzomib is the first in a new class,of spe...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Longs Drugs Partners With Google on the Launch of Google Health 19817 1Longs Drugs Partners With Google on the Launch of Google Health 19817 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 1bioMETRX Expands Engineering and Manufacturing Capabilities 3366 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 1TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 2TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 4Greener offices make happier employees 19812 1Greener offices make happier employees 19812 2
...itional Findings Reported on Glucose Homeostasis E...ne 25, 2007 /PRNewswire-FirstCall/ -- In a 14-day,... doses of the,investigational compound dapaglifloz...ansporter 2 (SGLT2) administered alone or,concomit...tes, no,discontinuations due to adverse events and...
...VILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/...hree Phase I trials,studying REP8839, a novel topi...vity against major skin pathogens including,methic...he Phase I,trials show that topically applied REP8...th low systemic exposure, or drug,absorption into ...
Other Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4
(Date:12/1/2008)...S, Dec. 2 While many Ame...ic challenges including rising costs of,basic nec...ess Scripts,(Nasdaq: ESRX ) has expanded Rx Out...escription medicines. , (Logo: http://www...OGO ) , Lower-income consumers can now rece...
(Date:12/1/2008)...O New research reveals that computed tomography (...y, has the potential to screen for two diseases at...hich commonly affect adults over age 50. Results o...meeting of the Radiological Society of North Ameri...to screening for colorectal cancer, we were able t...
(Date:12/1/2008)... Warren Presents Award, Engages with President on ...ome and Abroad During Saddleback Civil Forum on Gl...ire/ -- President George W. Bush was honored on th...he "International Medal of PEACE" given by Dr. Ric...uring the Saddleback Civil Forum on Global Health....
(Date:12/1/2008)...ls shut down and stop dividing when their DNA is d... so as to prevent damaged DNA from leading to unre...r, a new study, published in this week,s issue of ...ut down they also spew proteins into their surroun...s up conditions that support the development of ag...
Breaking Medicine News(10 mins):Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 2Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 3Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 4Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 3Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 4Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 5Health News:Escape cancer, but age sooner? The dark side of the tumor suppressing process 2
...em to be linked to extremely low frequency electro... of print in Occupational and Environmental Medic...wiss railway workers, who were monitored for 30 ye...opted to study this group, because railway workers...
...cials have confirmed the first human case of avian... The Ministry of Health has officially confirmed t...eadly H5N1 virus, two days after the suspected cas...ing to Vietnam News Agency. The man, from Vinh Ph...
...tudy by neurologists at the University of Arkansas...und a link between the increasingly popular weigh... serious neurological conditions. Katalin Juhasz...in the UAMS Department of Neurology, is lead autho...
...own that too much heat can decrease sperm count, a...the Bourn Hall Clinic in Cambridgeshire have sugge...ot be the best preparation for fathering a child. ...hat a foreign break develops their probability of ...
Other Medicine News:Health News:Link Between Gastric Bypass Surgery and Neurological Conditions 2
Fome-Cuf® tubes can breathe with the patient to provide a safe, effective, and low pressure seal throughout the ventilatory cycle.
The TTS™ tracheostomy tubes are available in both neonatal and pediatric sizes., ,The TTS™ tube is like an uncuffed tube, but it has a cuff. When completely deflated, it collapses tight
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions.
...l spiral reinforced. X-ray opaque . Low volume cuf...ange: The flange can be adjusted along the tube sh...sue. The lock ring is turned clockwise until the f...atient Comfort: The tube is soft and flexible for ...
Medicine Products: